LNSR

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

Wall Street analysts forecast LNSR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNSR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LENSAR Inc revenue for the last quarter amounts to 14.32M USD, increased 5.74 % YoY.

LENSAR Inc. EPS for the last quarter amounts to -0.31 USD, increased 138.46 % YoY.

LENSAR Inc (LNSR) has 140 emplpoyees as of December 16 2025.

Today LNSR has the market capitalization of 137.60M USD.